Chen Wu

Abstract 1213: Mitochondrial transcriptome profiles associated with clinical responses to CAR-T therapy in aggressive lymphoma.

Jacqueline A. Turner, Panwen Wang, Patrizia Mondello, Melinda Tan et autres

Abstract Introduction: Therapeutic outcomes in B-cell non-Hodgkin’s lymphoma (B-NHL) have substantially improved with the introduction of chimeric antigen receptor T-cell (CAR-T) therapy. Yet, persistent immune dysfunction and underlying metabolic dysregulation remain major obstacles to achieving durable clinical responses in B-NHL. We hypothesize …

us (code pays fourni par la source)

Abstract 3278: Metabolic pathway signatures defining response to CD19 CAR T-Cell therapy in aggressive B-cell non-hodgkin lymphoma

Melinda S.Y. Tan, Panwen Wang, Patrizia Mondello, Jacqueline A. Turner et autres

Abstract Chimeric antigen receptor (CAR) T-cell therapy achieves high response rates in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma, yet only 40% of patients achieve durable remission. Identifying biological programs linked to long-term response remains critical. As metabolic fitness underlies T-cell persistence and effector …

us (code pays fourni par la source)

Abstract 7935: Multimodal immunotherapy remodels the tumor microenvironment in hepatocellular carcinoma: Integrative spatial and transcriptomic profiling from a Phase II trial

Lionel Aurelien Kankeu Fonkoua, Christopher L. Hallemeier, Basim Salem, Arina V. Tkachuk et autres

Abstract Background: Hepatocellular carcinoma (HCC) is largely refractory to immune checkpoint blockade due to immune exclusion, stromal barriers, and aberrant vasculature. We evaluated whether multimodal therapy - external beam radiotherapy (EBRT) for antigen release, intratumoral dendritic cell (DC) vaccination for antigen presentation, …

us (code pays fourni par la source)

Abstract 6475: Myeloma cells with therapy-induced senescence-like phenotype have increased resistance to killing by T cell directed therapies

Christoph Schaefers, Angelo Jose Guilatco, Sofia Arbelaez, Gabriel Álvares Borges et autres

Abstract Background: Therapy-induced senescence (TIS), a tumor cell state associated with distinct gene expression patterns and implicated in therapy resistance, may be activated in Multiple Myeloma (MM) patients (pt) by genotoxic chemotherapies, such as high-dose melphalan (HDM). We investigated whether TIS is …

us (code pays fourni par la source)

Abstract 6467: Myeloma cells with therapy-induced senescence-like phenotype are associated with resistance to CAR-T therapy

Sofia Arbelaez, Andre de Menezes Silva Corraes, Gabriel Álvares Borges, Chen Wu et autres

Abstract Background: Patients (pts) with myeloma (MM) receiving CAR-T therapy have usually been exposed to many prior therapies. Melphalan (HDM) and other chemotherapies can induce cellular senescence. It has recently been shown that MM cells can also exhibit features of therapy-induced senescence …

us (code pays fourni par la source)

Abstract 3931: Immune cell profile changes in patients treated with tarlatamab for extensive stage small cell lung cancer in real world practice.

Dhauna Karam Prasad, Andre De Menezes Silva Corraes, Malvika Gupta, Audrey Ma et autres

Abstract Background: Tarlatamab, a Delta-like ligand (DLL3)/CD3-targeted bispecific T-cell engager (TCE) is FDA approved in patients (pts) with extensive stage small cell lung cancer (ES-SCLC), after progression on frontline chemoimmunotherapy. We aimed to evaluate the immune cell profile in pts who received …

us (code pays fourni par la source)

Abstract 5198: A non-viral mRNA engineering platform for rapid, same-day immune-cell therapies

Chen Wu, Christoph Schaefers, Malvika Gupta, Kevin M. Regan et autres

Abstract Background: Cellular immunotherapy has transformed cancer treatment, but success in solid tumors remains limited by long manufacturing times, high costs, and the need for viral vectors that permanently modify DNA. To address this, we examined electroporation (EP) and mechanoporation (MP) approach …

us (code pays fourni par la source)

Supplementary Fig. 6 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation

Han Wang, Yuxuan Luo, Sandeep Artham, Qianqian Wang et autres

Supplementary Fig. 6: Comparative pathway analysis reveals distinct transcriptional effects of MTO and fulvestrant

Supplementary Fig. 1 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation

Han Wang, Yuxuan Luo, Sandeep Artham, Qianqian Wang et autres

Supplementary Fig. 1: MTO, unlike fulvestrant, maintains E2-mediated ER-SRC3 interaction

Data from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation

Han Wang, Yuxuan Luo, Sandeep Artham, Qianqian Wang et autres

Abstract The estrogen receptor (ER or ERα) remains the primary therapeutic target for luminal breast cancer, with current treatments centered on competitive antagonists, receptor downregulators, and aromatase inhibitors. Despite these options, resistance frequently emerges, highlighting the need for alternative targeting strategies. We …

Supplementary Fig. 5 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation

Han Wang, Yuxuan Luo, Sandeep Artham, Qianqian Wang et autres

Supplementary Fig. 5: ER protein levels in wild-type and Y537S ER orthotopic xenograft tumors

Supplementary Fig. 2 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation

Han Wang, Yuxuan Luo, Sandeep Artham, Qianqian Wang et autres

Supplementary Fig. 2: MTO demonstrates enhanced growth inhibition in endocrine-resistant T47D cells